Nothing Special   »   [go: up one dir, main page]

EA201391515A1 - Инактивированная вакцина вируса денге - Google Patents

Инактивированная вакцина вируса денге

Info

Publication number
EA201391515A1
EA201391515A1 EA201391515A EA201391515A EA201391515A1 EA 201391515 A1 EA201391515 A1 EA 201391515A1 EA 201391515 A EA201391515 A EA 201391515A EA 201391515 A EA201391515 A EA 201391515A EA 201391515 A1 EA201391515 A1 EA 201391515A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inactivated
virus vaccine
denge
denge virus
preparation
Prior art date
Application number
EA201391515A
Other languages
English (en)
Inventor
Вероник Эндерикс
Оливье Ле Бусси
Доминик Ингрид Лемуан
Фредерик Мато
Original Assignee
Глаксосмитклайн Байлоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байлоджикалс С.А. filed Critical Глаксосмитклайн Байлоджикалс С.А.
Publication of EA201391515A1 publication Critical patent/EA201391515A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем изобретении предлагаются препараты иммуногенной композиции, содержащей очищенный инактивированный вирус Денге, и способы их получения.
EA201391515A 2011-05-26 2012-05-25 Инактивированная вакцина вируса денге EA201391515A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490205P 2011-05-26 2011-05-26
US201161570966P 2011-12-15 2011-12-15
PCT/EP2012/059879 WO2012160199A1 (en) 2011-05-26 2012-05-25 Inactivated dengue virus vaccine

Publications (1)

Publication Number Publication Date
EA201391515A1 true EA201391515A1 (ru) 2014-05-30

Family

ID=46148894

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391515A EA201391515A1 (ru) 2011-05-26 2012-05-25 Инактивированная вакцина вируса денге

Country Status (15)

Country Link
US (1) US20140112953A1 (ru)
EP (1) EP2714076A1 (ru)
JP (1) JP2014515367A (ru)
KR (1) KR20140033171A (ru)
CN (2) CN103619349A (ru)
AU (2) AU2012260807B2 (ru)
BR (1) BR112013030236A2 (ru)
CA (1) CA2837145A1 (ru)
CO (1) CO6811814A2 (ru)
EA (1) EA201391515A1 (ru)
IL (1) IL229307A0 (ru)
MX (1) MX349119B (ru)
PE (1) PE20140646A1 (ru)
SG (1) SG194950A1 (ru)
WO (1) WO2012160199A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145149A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
CN107921063A (zh) 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
WO2017053873A1 (en) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
GB201522068D0 (en) 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
BE1024160A9 (fr) * 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
WO2017210215A1 (en) * 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
CN110139671A (zh) 2016-11-16 2019-08-16 普莱瓦克斯免疫肿瘤学公司 用于治疗癌症的组合免疫疗法
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
CN107140625A (zh) * 2017-06-14 2017-09-08 中国海洋大学 一种利用植物油制备石墨烯薄膜的方法
WO2019090238A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
MX2020005554A (es) 2017-11-30 2020-10-12 Takeda Vaccines Inc Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
JP7042341B2 (ja) 2017-12-07 2022-03-25 メルク・シャープ・アンド・ドーム・コーポレーション デングウイルスワクチン組成物の製剤
US20240076631A2 (en) * 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
CN112546213A (zh) * 2020-12-31 2021-03-26 中国医学科学院医学生物学研究所 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用
CN115531529A (zh) * 2022-09-16 2022-12-30 大连理工大学 一种冻干保护剂在含铝佐剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
CZ2003930A3 (cs) * 2000-10-02 2003-08-13 Glaxosmithkline Biologicals S. A. Vakcinační prostředek obsahující štěpený virus s obalem
RU2358763C2 (ru) * 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
WO2006078294A2 (en) * 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
EP1951865A4 (en) * 2005-11-21 2010-06-23 Sanofi Pasteur Ltd STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES
AU2008279576C1 (en) * 2007-04-06 2014-01-23 Takeda Vaccines, Inc. Methods and compositions for live attenuated viruses
ES2564183T3 (es) * 2008-09-29 2016-03-18 Cadila Pharmaceuticals Ltd. Adyuvantes de vacuna
KR101738704B1 (ko) * 2009-02-17 2017-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 알루미늄-비함유 아주반트를 포함하는 불활성화 뎅기 바이러스 백신
US9005633B2 (en) * 2009-07-17 2015-04-14 The United States Of America As Represented By The Secretary Of The Navy. Psoralen-inactivated viral vaccine and method of preparation
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine

Also Published As

Publication number Publication date
JP2014515367A (ja) 2014-06-30
MX349119B (es) 2017-07-12
SG194950A1 (en) 2013-12-30
US20140112953A1 (en) 2014-04-24
CA2837145A1 (en) 2012-11-29
CN107050445A (zh) 2017-08-18
PE20140646A1 (es) 2014-05-29
CO6811814A2 (es) 2013-12-16
AU2016210743A1 (en) 2016-08-25
IL229307A0 (en) 2014-01-30
WO2012160199A1 (en) 2012-11-29
AU2012260807B2 (en) 2016-05-12
MX2013013862A (es) 2014-01-23
CN103619349A (zh) 2014-03-05
BR112013030236A2 (pt) 2016-12-06
EP2714076A1 (en) 2014-04-09
KR20140033171A (ko) 2014-03-17

Similar Documents

Publication Publication Date Title
EA201391515A1 (ru) Инактивированная вакцина вируса денге
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
EA201790781A2 (ru) Противовирусные соединения
EA201390576A1 (ru) Противовирусные соединения
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
EA201790963A1 (ru) Противовирусные соединения
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201790630A1 (ru) Способы получения рибозидов
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
EA201790661A3 (ru) Ингибиторы вируса гепатита c
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201391495A1 (ru) Производные пиримидина для лечения вирусных инфекций
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA202090547A3 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
EA201690372A1 (ru) Азапиридоновые соединения и их применение
EA201792407A3 (ru) Композиции, содержащие буфер, составы вакцин, которые содержат композиции, содержащие буфер, и пути их применения
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201591451A1 (ru) Модуляторы flap
EA201390856A1 (ru) Инактивация вирусов с применением улучшенного способа растворитель-детергент